Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two drugs, n-acetylcysteine and ketamine. N-acetylcysteine (NAC) is an antioxidant and precursor to glutathione, primarily used as a mucolytic agent and for the treatment of acetaminophen overdose. It has neuroprotective properties and modulates glutamate neurotransmission via the cystine-glutamate antiporter. Ketamine is a dissociative anesthetic that acts as an N-methyl-D-aspartate (NMDA) receptor antagonist; it is used for anesthesia, pain management, and increasingly in psychiatric indications such as depression due to its rapid-acting antidepressant effects. Preclinical studies indicate that co-administration of NAC with ketamine can prevent or ameliorate ketamine-induced toxicities—including cardiotoxicity, developmental toxicity, neurotoxicity affecting monoaminergic neurons—and behavioral deficits in animal models. The combination may be explored for reducing adverse effects associated with ketamine therapy or enhancing neuroprotection during its use[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-acetylcysteine + ketamine.